Literature DB >> 1471873

The oxidant stress hypothesis in Parkinson's disease: evidence supporting it.

S Fahn1, G Cohen.   

Abstract

Oxidant stress, due to the formation of hydrogen peroxide and oxygen-derived free radicals, can cause cell damage due to chain reactions of membrane lipid peroxidation. Because the substantia nigra is rich in dopamine, which can undergo both enzymatic oxidation via monoamine oxidase and nonenzymatic autoxidation, hydrogen peroxide and oxyradicals (superoxide anion radical and hydroxyl radical) are generated in this midbrain nucleus. Although proof that oxidant stress actually causes the loss of monoaminergic neurons in patients with Parkinson's disease is lacking, there is a considerable body of evidence from studies in both animals and humans that support the concept. (1) Neurotoxins that selectively destroy the dopaminergic neurons in the nigra, such as 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), appear to act via oxidant stress. (2) The substantia nigra of patients with Parkinson's disease reveals evidence of oxidant stress by the findings of increased lipid peroxidation and decreased reduced glutathione. (3) Total iron is increased and ferritin is reduced in the substantia nigra pars compacta in patients with Parkinson's disease. This combination suggests that this transition metal is in a low molecular weight form, capable of catalyzing nonenzymatic oxidative reactions, especially the conversion of hydrogen peroxide to hydroxyl radical, which is the most reactive of the oxygen radicals. (4) Neuromelanin, a product of dopamine autoxidation, can serve as a reservoir for iron, promoting the generation of oxyradicals. (5) Antioxidant defense mechanisms appear to be reduced in the parkinsonian substantia nigra with the findings of decreased activities of glutathione peroxidase and catalase.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1471873     DOI: 10.1002/ana.410320616

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  155 in total

1.  Nuclear translocation of anamorsin during drug-induced dopaminergic neurodegeneration in culture and in rat brain.

Authors:  Kyung-Ah Park; Nuri Yun; Dong-Ik Shin; So Yoen Choi; Hyun Kim; Won-Ki Kim; Yuzuru Kanakura; Hirohiko Shibayama; Young J Oh
Journal:  J Neural Transm (Vienna)       Date:  2010-10-06       Impact factor: 3.575

Review 2.  Potential role of cannabinoids in Parkinson's disease.

Authors:  J Sevcík; K Masek
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

3.  Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine.

Authors:  R Pedrosa; P Soares-da-Silva
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 4.  Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson's disease.

Authors:  Julie K Andersen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

5.  Experimental strategy to identify genes susceptible to oxidative stress in nigral dopaminergic neurons.

Authors:  Myung S Yoo; Hibiki Kawamata; Dae J Kim; Hong S Chun; Jin H Son
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

Review 6.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

Review 7.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

8.  Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease.

Authors:  Jose L Labandeira-Garcia; Jannette Rodriguez-Pallares; Ana I Rodríguez-Perez; Pablo Garrido-Gil; Begoña Villar-Cheda; Rita Valenzuela; Maria J Guerra
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

9.  Model neuromelanins as antioxidative agents during lipid peroxidation.

Authors:  T Wilczok; K Stepien; A Dzierzega-Lecznar; A Zajdel; A Wilczok
Journal:  Neurotox Res       Date:  1999-12       Impact factor: 3.911

Review 10.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.